New drug cocktail targets Hard-to-Treat myeloma spread

NCT ID NCT04166565

Ongoing Disease control Sponsor: Stichting European Myeloma Network Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread outside the bones, known as extramedullary disease. The goal is to see how well the treatment works and how safe it is. Participants are either newly diagnosed or have had only one prior treatment, and they are followed for up to 5 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRAMEDULLARY PLASMACYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extramedullary plasmacytoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTRAMEDULLARY PLASMACYTOMA MULTIPLE MYELOMA

Contacts and locations

Locations

Ankara University

Ankara, Turkey (Türkiye)
Anticancer Hospital of Thessaloniki

Thessaloniki, Greece
Dokuz Eylul University

Balçova, Turkey (Türkiye)
Erciyes University

Kayseri, Turkey (Türkiye)
Marmara University

Pendik, Turkey (Türkiye)
Univerity of Turin

Torino, Italy
University of Athens

Athens, Greece
University of Bologna

Bologna, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.